Gene expression profiles for predicting the efficacy of the anticancer drug 5-fluorouracil in breast cancer

DNA and Cell Biology

Volumn 29, Issue 6, 2010, Pages 285-293

  Tsao, Der An ^a,b   Chang, Hui Jen ^a,b   Lin, Chi Ying ^c   Hsiung, Suz Kai ^a,b   Huang, Seng Eng ^c   Ho, Shiu Yen ^b   Chang, Ming Sung ^b   Chiu, Hua Hsien ^a   Chen, Yi Fang ^d   Cheng, Tian Lu ^e   Shiu Ru, Lin ^a,b  

^a FOOYIN UNIVERSITY   (Taiwan)

^b FOOYIN UNIVERSITY HOSPITAL   (Taiwan)

^c PINGTUNG CHRISTIAN HOSPITAL   (Taiwan)

^d Gene Target Technology Co Ltd   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CCL28 CHEMOKINE; CHEMOKINE; COPPER ZINC SUPEROXIDE DISMUTASE; CXCL2 CHEMOKINE; FLUOROURACIL; INTERLEUKIN 18; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ARTICLE; ASIAN; BIOINFORMATICS; BREAST CANCER; CANCER CELL CULTURE; CHI3L1 GENE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FAM46A GENE; FDXR GENE; GENE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENE PROBE; HUMAN; HUMAN CELL; HUMAN TISSUE; MICROARRAY ANALYSIS; ONCOGENE H RAS; PLEKHA8 GENE; PREDICTION; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CELL LINE, TUMOR; FLUOROURACIL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; INHIBITORY CONCENTRATION 50; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REPRODUCIBILITY OF RESULTS;

EID: 77953947091     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/dna.2009.1006     Document Type: Article

References (30)

1. Barrett-Lee, P.J. (2005). Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: a review of chemotherapy. Endocr Relat Cancer 12 Suppl 1, S125-S133.
2. Bureau of Health Protection. (2002). Cancer Registry Annual Report. (Department of Health, R.O.C., Taipei, Taiwan).
3. Ellis, M., and Ballman, K. (2004). Trawling for genes that predict response to breast cancer adjuvant therapy. J Clin Oncol 22, 2267-2269.
4. Engelsman, E., Korsten, C.B., Persijn, J.P., and Cleton, F.J. (1974). Letter: anti-oestrogens and breast cancer. Lancet 2, 171-172.
5. Glazer, R.I., and Lloyd, L.S. (1982). Association of cell lethality with incorporation of 5-fluorouracil and 5-fluorouridine into nuclear RNA in human colon carcinoma cells in culture. Mol Pharmacol 21, 468-473.
6. Hakamada, Y., Tsuchida, A., Arima, M., Kubouchi, T., Tokita, H., Ota, D., Kaise, H., Aoki, T., Kusama, M., and Aoki, T. (2005). Prognostic predictors in breast cancer patients with postoperative 5-fluorouracil-based chemotherapy. Int J Mol Med 16, 309-314.
7. Ichikawa, W., Ooyama, A., Toda, E., Sugimoto, Y., Oka, T., Takahashi, T., Shimizu, M., Sasaki, Y., and Hirayama, R. (2006). Gene expression of ferredoxin reductase predicts outcome in patients with metastatic colorectal cancer treated by 5-fluorouracil plus leucovorin. Cancer Chemother Pharmacol 58, 794-801.
8. Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Smigal, C., and Thun, M.J. (2006). Cancer statistics, 2006. CA Cancer J Clin 56, 106-130.
9. Kufe, D.W., and Major, P.P. (1981). 5-Fluorouracil incorporation into human breast carcinoma RNA correlates with cytotoxicity. J Biol Chem 256, 9802-9805.
10. Ladner, R.D. (2001). The role of dUTPase and uracil-DNA repair in cancer chemotherapy. Curr Protein Pept Sci 2, 361-370.
11. Lenz, H.J. (2003). Pharmacogenomics in colorectal cancer. Semin Oncol 30, 47-53.
12. MacGrogan, G., Bonichon, F., de Mascarel, I., Trojani, M., Durand, M., Avril, A., and Coindre, J.M. (1995). Prognostic value of p53 in breast invasive ductal carcinoma: an immunohistochemical study on 942 cases. Breast Cancer Res Treat 36, 71-81.
13. Martin-Richard, M., Muñoz, M., Albanell, J., Colomo, L., Bellet, M., Rey, M.J., Tabernero, J., Alonso, C., Cardesa, A., Gascon, P., and Fernandez, P.L. (2004). Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy. Oncology 66, 388-394.
14. Maxwell, P.J., Longley, D.B., Latif, T., Boyer, J., Allen, W., Lynch, M., McDermott, U., Harkin, D.P., Allegra, C.J., and Johnston, P.G. (2003). Identification of 5-fluorouracil-inducible target genes using cDNA microarray profiling. Cancer Res 63, 4602-4606.
15. Modlich, O., Prisack, H.B., Munnes, M., Audretsch, W., and Bojar, H. (2005). Predictors of primary breast cancers responsiveness to preoperative epirubicin=cyclophosphamide-based chemotherapy: translation of microarray data into clinically useful predictive signatures. J Transl Med 3, 32-50.
16. National Health Research Institute. (1998). Consensus in Diagnosis and Treatment of Breast Cancer. Available at www.nhri.org .tw. (Taipei, Taiwan).
17. Ogston, K.N., Miller, I.D., Schofield, A.C., Spyrantis, A., Pavlidou, E., Sarkar, T.K., Hutcheon, A.W., Payne, S., and Heys, S.D. (2004). Can patients'likelihood of benefiting from primary chemotherapy for breast cancer be predicted before commencement of treatment? Breast Cancer Res Treat 86, 181-189.
18. Perloff, M., Norton, L., Korzun, A.H., Wood, W.C., Carey, R.W., Gottlieb, A., Aust, J.C., Bank, A., Silver, R.T., Saleh, F., Canellos, G.P., Perry, M.C., Weiss, R.B., and Holland, J.F. (1996). Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a cancer and leukemia group B study. J Clin Oncol 14, 1589-1598.
19. Ponomaryov, T., Peled, A., Petit, I., Taichman, R.S., Habler, L., Sandbank, J., Arenzana-Seisdedos, F., Magerus, A., Caruz, A., Fujii, N., Nagler, A., Lahav, M., Szyper-Kravitz, M., Zipori, D., and Lapidot, T. (2000). Induction of the chemokine stromalderived factor-1 following DNA damage improves human stem cell function. J Clin Invest 106, 1331-1339.
20. Pusztai, L., and Gianni, L. (2004). Technology insight: emerging techniques to predict response to preoperative chemotherapy in breast cancer. Nat Clin Pract Oncol 1, 44-50.
21. Scherf, U., Ross, D.T., Waltham, M., Smith, L.H., Lee, J.K., Tanabe, L., Kohn, K.W., Reinhold, W.C., Myers, T.G., Andrews, D.T., Scudiero, D.A., Eisen, M.B., Sausville, E.A., Pommier, Y., Botstein, D., Brown, P.O., and Weinstein, J.N. (2000). A gene expression database for the molecular pharmacology of cancer. Nat Genet 24, 236-244. (Pubitemid 30132190)
22. Shanaz, H.D., Youngran, J.,Yong, B., Dan, H.M., Zhenhang, M., Stefanie, S.J., and Dairkee, S.H. (2004). A molecular "signature" of primary breast cancer cultures; patterns resembling tumor tissue. BMC Genomics 5, 47-56.
23. Sjöström, J., Blomqvist, C., Heikkilä , P., Boguslawski, K.V., Rä isänen-Sokolowski, A., Bengtsson, N.O., Mjaaland, I., Malmström, P., Ostenstadt, B., Bergh, J., Wist, E., Valvere, V., and Saksela, E. (2000). Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer. Clin Cancer Res 6, 3103-3110.
24. Smith, H.S., Zoli, W., Volpi, A., Hiller, A., Lippman, M., Swain, S., Mayall, B., Dollbaum, C., Hackett, A.J., and Amadori, D. (1990). Preliminary correlations of clinical outcome with in vitro chemosensitivity of second passage human breast cancer cells. Cancer Res 50, 2943-2948.
25. Sotiriou, C, Powles, T.J., Dowsett, M., Jazaeri, A.A., Feldman, A.L., Assersohn, L., Gadisetti, C., Libutti, S.K., and Liu, E.T. (2002). Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res 4, 1-8.
26. Troester, M.A., Hoadley, K.A., Sørlie, T., Herbert, B.S., Børresen-Dale, A.L., Lønning, P.E., Shay, J.W., Kaufmann, W.K., and Perou, C.M. (2004). Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res 64, 4218-4226.
27. van't Veer, L.J., Dai, H., Hart, A.A., Voskuil, D.W., Schreiber, G.J., Peterse, J.L., Roberts, C., Marton, M.J., Parrish, M., Atsma, D., Witteveen, A., Glas, A., Delahaye, L., van der Velde, T., Bartelink, H., Rodenhuis, S., Rutgers, E.T., Friend, S.H., and Bernards, R. (2002). A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347, 1999-2009. (Pubitemid 35461656)
28. Verschraegen, C.F., Hu, W., Du, Y., Mendoza, J., Early, J., Deavers, M., Freedman, R.S., Bast, R.C.J., Kudelka, A.P., Kavanagh, J.J., and Giovanella, B.C. (2003). Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers. Clin Cancer Res 9, 845-852.
29. Webley, S.D., Hardcastle, A., Ladner, R.D., Jackman, A.L., and Aherne, G.W. (2000). Deoxyuridine triphosphatase (dUTPase) expression and sensitivity to the thymidylate synthase (TS) inhibitor ZD9331. Br J Cancer 83, 792-799.
30. Yu, J., Marsh, S., Ahluwalia, R., and McLeod, H.L. (2003). Ferredoxin reductase: pharmacogenomic assessment in colorectal cancer. Cancer Res 63, 6170-6173.